Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Edmondson

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 28, 2022
High detection rate from genetic testing in BRCA-negative women with familial epithelial ovarian cancerNicola Flaum, Emma J Crosbie, Richard Edmondson, et al.
Clinical Genetics|September 29, 2021
Dominant-negative pathogenic variant BRIP1 c.1045G>C is a high-risk allele for non-mucinous epithelial ovarian cancer: A case-control studyNicola Flaum, Elke M van Veen, Olivia Smith, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 22, 2013
Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational eraCarien L Creutzberg, Henry C Kitchener, Michael J Birrer, et al.
Oncotarget|October 22, 2015
Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibitionFiona K Middleton, Miranda J Patterson, Claire J Elstob, et al.
Cancers|January 11, 2024
Analysis of Anxiety, Depression and Fear of Progression at 12 Months Post-Cytoreductive Surgery in the SOCQER-2 (Surgery in Ovarian Cancer-Quality of Life Evaluation Research) Prospective, International, Multicentre StudyAarti Lakhiani, Carole Cummins, Satyam Kumar, et al.
Journal of Medical Genetics|February 11, 2021
Uptake and efficacy of bilateral risk reducing surgery in unaffected female <i>BRCA1</i> and <i>BRCA2</i> carriersRuta Marcinkute, Emma Roisin Woodward, Ashu Gandhi, et al.
BMJ Open Quality|February 25, 2025
Developing a platform to investigate the heterogeneity of outcomes for patients with ovarian cancerKathryn Baxter, J Booth, A Hawarden, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|December 5, 2021
Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort studySudha Sundar, Carole Cummins, Satyam Kumar, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|April 25, 2017
BGCS uterine cancer guidelines: Recommendations for practiceSudha Sundar, Janos Balega, Emma Crosbie, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 20, 2021
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for <i>BRCA</i>1/2 variants in ovarian cancer in the United KingdomSudha Sundar, Ranjit Manchanda, Charlie Gourley, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 28, 2022
High detection rate from genetic testing in BRCA-negative women with familial epithelial ovarian cancerNicola Flaum, Emma J Crosbie, Richard Edmondson, et al.
Clinical Genetics|September 29, 2021
Dominant-negative pathogenic variant BRIP1 c.1045G>C is a high-risk allele for non-mucinous epithelial ovarian cancer: A case-control studyNicola Flaum, Elke M van Veen, Olivia Smith, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 22, 2013
Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational eraCarien L Creutzberg, Henry C Kitchener, Michael J Birrer, et al.
Oncotarget|October 22, 2015
Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibitionFiona K Middleton, Miranda J Patterson, Claire J Elstob, et al.
Cancers|January 11, 2024
Analysis of Anxiety, Depression and Fear of Progression at 12 Months Post-Cytoreductive Surgery in the SOCQER-2 (Surgery in Ovarian Cancer-Quality of Life Evaluation Research) Prospective, International, Multicentre StudyAarti Lakhiani, Carole Cummins, Satyam Kumar, et al.
Journal of Medical Genetics|February 11, 2021
Uptake and efficacy of bilateral risk reducing surgery in unaffected female <i>BRCA1</i> and <i>BRCA2</i> carriersRuta Marcinkute, Emma Roisin Woodward, Ashu Gandhi, et al.
BMJ Open Quality|February 25, 2025
Developing a platform to investigate the heterogeneity of outcomes for patients with ovarian cancerKathryn Baxter, J Booth, A Hawarden, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|December 5, 2021
Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort studySudha Sundar, Carole Cummins, Satyam Kumar, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|April 25, 2017
BGCS uterine cancer guidelines: Recommendations for practiceSudha Sundar, Janos Balega, Emma Crosbie, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 20, 2021
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for <i>BRCA</i>1/2 variants in ovarian cancer in the United KingdomSudha Sundar, Ranjit Manchanda, Charlie Gourley, et al.
Pageof 3